Research progress of radiopharmaceuticals targeting carbonic anhydrase IX
XIE Jiajian
FENG Yue
ZHANG Huihui
CAI Liang
Abstract：The tumor microenvironment plays an important role in tumorigenesis,development,metastasis,and drug sensitivity.Carbonic anhydrase IX(CAIX)is a metalloenzyme that is highly expressed in certain tumor microenvironments and is closely related to tumor cell genesis,development and drug resistance.Its high expression in tumors and low expression in normal tissues makes it a potential target for the diagnosis and treatment of a variety of tumors.With the in-depth research on antitumor drugs and radionuclide-targeted therapy targeting CAIX,the detection of CAIX expression using noninvasive radiopharmaceuticals has become more urgent in order to meet the strategy of diagnostic and therapeutic integration.In this paper,we summarize and review the research on CAIX-targeting radiopharmaceuticals in recent years,analyze and summarize the advantages and disadvantages of monoclonal antibodies,small molecules and peptides,as well as the prospects of their clinical application,so as to optimize the structure of the drugs,reduce the side effects and meet the clinical needs,and to accelerate the clinical application of these drugs.
Keywords：carbonic anhydraseclear cell renal cell carcinomaradiopharmaceuticalsreview
Publication Date：2025-06-20
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 776-780 )